Nephros Inc
NASDAQ: NEPH · HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES
Updated 2026-06-05
Nephros Inc (NEPH) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for NEPH.
Current price exceeds what fundamentals support. Risk/reward skewed unfavorably.
NEPH historical valuation range
Where current P/E sits in NEPH's own 5Y range.
NEPH intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
NEPH valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
Current: 48.43x
P/S Ratio — History
Current: 1.93x
Is NEPH overvalued in 2026?
Nephros Inc (NEPH) currently trades at $3.01 per share with a market capitalization of $36,803,700.00. Based on our multi-factor framework, the stock appears richly valued with a Smart Value Score of 32/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
The stock trades at a P/E ratio of 48.4x, above its 5-year median of 28.6x.
Looking at its own history, NEPH is currently trading more expensive than 87% of the last 5Y on P/E. This places it in the 87th percentile of its historical range, a zone where forward returns have typically been muted.
Our discounted cash flow model estimates NEPH's intrinsic value at $4.34 per share, against the current market price of $3.01. This implies a margin of safety of +6.91%. The stock is priced close to its estimated fair value, offering limited upside without further operational improvement.
Financial quality is a concern. The Piotroski F-Score of 3/9 flags weakening fundamentals that deserve closer scrutiny before the valuation case can be fully trusted.
Bottom line: NEPH appears richly valued on our framework, with a Smart Value Score of 32/100. At current levels the risk/reward is skewed against the buyer. A materially lower price or significant operational improvement would be needed to change the picture.
Frequently asked questions
Is NEPH overvalued?
NEPH scores 32/100 on our Smart Value Score (Grade F), a weak overall profile. The DCF also shows a positive margin of safety, so price and fundamentals line up reasonably well.
What is NEPH's fair value?
Our DCF model estimates NEPH's intrinsic value at $4.34 per share, versus the current price of $3.01, a margin of safety of +6.91%. Fair value is the present value of the cash flows we project the business to produce, so a price below it means the market is pricing the stock below that conservative estimate.
What P/E ratio does NEPH trade at?
NEPH trades at a P/E of 48.4x on trailing twelve-month earnings, against a 5-year median of 28.6x. P/E is what you pay per dollar of profit, and sitting above its own median means the stock is pricier than usual relative to its earnings.
Is NEPH a buy based on valuation?
Our Smart Value rating for NEPH is Strong Sell, from a Smart Value Score of 32/100 that blends growth, quality, and valuation. The profile skews cautious, and a better price or clearer operating improvement would strengthen the case. This is research to inform your decision, not personalized financial advice.
How does NEPH's valuation compare to its history?
On P/E, NEPH sits in the 87th percentile of its own 5Y range, historically expensive relative to where it has traded. A high percentile means today's multiple is near the top of its historical band.
What is NEPH's Smart Value Score?
NEPH's Smart Value Score is 32/100. It is a proprietary WallStSmart metric blending growth quality, financial health, and valuation into a single 0-100 read, and scores above 75 are rare, signaling strong multi-factor alignment.